AFMD | tickerfilter.com

Fundamental analysis

33%

Profitability 25%

Dept financing 18%

Liquidity 75%

Performance 35%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-0.02%

1 Month

-38.38%

3 Months

-51.69%

6 Months

-81.61%

1 Year

-90.66%

2 Year

-91.47%

Key data

Stock price

$0.57

P/E Ratio

0.00

DAY RANGE

$0.57 - $0.62

EPS

-$0.64

52 WEEK RANGE

$0.52 - $8.95

52 WEEK CHANGE

-$90.22

MARKET CAP

93.337 M

YIELD

N/A

SHARES OUTSTANDING

15.227 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

04-15-2025

BETA

2.56

PUBLIC FLOAT

AVERAGE 10 VOLUME

$163,674

AVERAGE 30 VOLUME

$116,526

Company detail

CEO: Adolf Hoess
Region: US
Website: affimed.com
Employees: 200
IPO year: 2014

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Affimed N.V. focuses on discovering and developing cancer immunotherapies. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers.

AFMD - Affimed N.V.